Biomea Fusion Inc (BMEA) - Total Assets
Based on the latest financial reports, Biomea Fusion Inc (BMEA) holds total assets worth $46.38 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Biomea Fusion Inc (BMEA) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Biomea Fusion Inc - Total Assets Trend (2019–2025)
This chart illustrates how Biomea Fusion Inc's total assets have evolved over time, based on quarterly financial data. See BMEA net asset value for net asset value and shareholders' equity analysis.
Biomea Fusion Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Biomea Fusion Inc's total assets of $46.38 Million consist of 99.1% current assets and 0.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 95.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Biomea Fusion Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see BMEA market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biomea Fusion Inc's current assets represent 99.1% of total assets in 2025, a decrease from 100.0% in 2019.
- Cash Position: Cash and equivalents constituted 95.3% of total assets in 2025, up from 90.2% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Biomea Fusion Inc Competitors by Total Assets
Key competitors of Biomea Fusion Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Biomea Fusion Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.98 | 2.25 | 40.57 |
| Quick Ratio | 4.98 | 2.25 | 40.57 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $37.02 Million | $24.87 Million | $195.58 Million |
Biomea Fusion Inc - Advanced Valuation Insights
This section examines the relationship between Biomea Fusion Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.63 |
| Latest Market Cap to Assets Ratio | 1.44 |
| Asset Growth Rate (YoY) | -26.7% |
| Total Assets | $58.57 Million |
| Market Capitalization | $84.59 Million USD |
Valuation Analysis
Above Book Valuation: The market values Biomea Fusion Inc's assets above their book value (1.44x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Biomea Fusion Inc's assets decreased by 26.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Biomea Fusion Inc (2019–2025)
The table below shows the annual total assets of Biomea Fusion Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $58.57 Million | -26.73% |
| 2024-12-31 | $79.94 Million | -60.02% |
| 2023-12-31 | $199.93 Million | +54.61% |
| 2022-12-31 | $129.31 Million | -30.37% |
| 2021-12-31 | $185.71 Million | +197.00% |
| 2020-12-31 | $62.53 Million | +23494.72% |
| 2019-12-31 | $265.00K | -- |
About Biomea Fusion Inc
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase I… Read more